http://orcid.org/0000-0002-0250-8559
References
- Jussila A, Virta LJ, Kautiainen H, et al. Increasing incidence of inflammatory bowel diseases between 2000 and 2007: a nationwide register study in Finland. Inflamm Bowel Dis. 2012;18:555–561.
- Burisch J, Munkholm P. The epidemiology of inflammatory bowel disease. Scand J Gastroenterol. 2015;50:942–951.
- Elkjaer M, Shuhaibar M, Burisch J, et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided ‘Constant-care’ approach. Gut. 2010;59:1652–1661.
- Aguas M, Del Hoyo J, Faubel R, et al. Use of telemedicine in inflammatory bowel disease: a real monitoring option? Exp Rev Gastroenterol Hepatol. 2016;10:879–881.
- Vinding KK, Elsberg H, Thorkilgaard T, et al. Fecal calprotectin measured by patients at home using smartphones–a new clinical tool in monitoring patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22:336–344.
- Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labeled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol. 1999;34:50–54.
- Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119:15–22.
- Molander P, Färkkilä M, Ristimäki A, et al. Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission? J Crohn's Colitis. 2015;9:33–40.
- Heida A, Knol M, Kobold AM, et al. Agreement between home-based measurement of stool calprotectin and ELISA results for monitoring inflammatory bowel disease activity. Clin Gastroenterol Hepatol. 2017;15:1742–1749.
- Elkjaer M, Burisch J, Voxen Hansen V, et al. A new rapid home test for faecal calprotectin in ulcerative colitis. Aliment Pharmacol Ther. 2009;31:323–330.
- Rogler G, Aldeguer X, Kruis W, et al. Concept for a rapid point-of-care calprotectin diagnostic test for diagnosis and disease activity monitoring in patients with inflammatory bowel disease: expert clinical opinion. J Crohn's Colitis. 2013;7:670–677.
- Puolanne A, Kolho K, Alfthan H, et al. Rapid faecal tests for detecting disease activity in colonic IBD. Eur J Clin Invest. 2016;46:825–832.
- de Jong MJ, van der Meulen-de Jong AE, Romberg-Camps MJ, et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet. 2017;390:959–968.
- Puolanne A, Kolho K, Alfthan H, et al. Rapid fecal calprotectin test and symptom index in monitoring the disease activity in colonic inflammatory bowel disease. Dig Dis Sci. 2017;62:3123–3130.
- Sintonen H. The 15D instrument of health-related quality of life: properties and applications. Ann Med. 2001;33:328–336.
- Haapamäki J, Andrea T, Harri S, et al. Health‐related quality of life among patients with primary sclerosing cholangitis. Liver Int. 2015;35:2194–2201.
- Robinson A, Thompson DG, Wilkin D, et al. Guided self-management and patient-directed follow-up of ulcerative colitis: a randomised trial. Lancet. 2001;358:976–981.
- Cross RK, Jambaulikar G, Langenberg P, et al. TELEmedicine for patients with inflammatory bowel disease (TELE-IBD): design and implementation of randomized clinical trial. Contemp Clin Trials. 2015;42:132–144.
- Bossuyt P, Pouillon L, Bonnaud G, et al. E-health in inflammatory bowel diseases: more challenges than opportunities? Dig Liver Dis. 2017;49:1320–1326.